Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-03

FDA Approved: TRODELVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TRODELVY (sacituzumab govitecan) from Gilead Sciences, Inc. The approval reflects action on the supplemental sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRODELVY (sacituzumab govitecan)

Snippet

SUPPL AP for TRODELVY (SACITUZUMAB GOVITECAN)